Allegro ’s Phase IIb stage 2 trial for DME drug meets primary endpoint

Biotechnology firm Allegro Ophthalmics has reported positive top-line results from the DEL MAR Phase IIb stage 2 clinical trial of luminate as a sequential therapy to treat diabetic macular edema (DME) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news